Medical Product Q1 Earnings On May 8: ITGR, OPK & More
Zacks Investment Research | May 04, 2017 09:33PM ET
The Q1 reporting cycle is at its last lap with 358 S&P members (78.2% of the total market cap) having already reported their quarterly numbers. For Medical, one of the 16 broader Zacks sectors, we have results from 84.5% of total market cap.
Per the latest Medical - Products industry registered growth of 8.8% in the last three months, comfortably outperforming the S&P 500 Index’s gain of 4.5%.
Notably, the growth story in the space exclusively pertains to the market dynamics and the shift in consumer demand, courtesy of the growing prevalence of minimally invasive surgeries, liquid biopsy tests, and use of IT for ensuring quick and improved patient care among other things. Furthermore, cost-effective products and techniques targeting emerging markets raise optimism.
On the flipside, the recent political conundrum in the healthcare space pertaining to the ‘Trumpcare’ is a headwind. Amid such unpredictability, let us take a look at how the players of this industry are positioned this earnings season.
Let’s take a look at the major Medical products stocks expected to release their first-quarter 2017 reports around May 8:
Integer Holdings Corporation (NYSE:ITGR) : It is one of the largest medical device outsource manufacturers in the world serving the cardiac, neuromodulation, orthopedics, vascular, advanced surgical and portable medical markets.
However, our proven model does not conclusively show that Integer Holdings is likely to beat earnings this quarter. A stock needs to have both a positive Earnings ESP Filter .
Opko Health, Inc. (NASDAQ:OPK) : OPKO Health is a diversified healthcare company that seeks to establish industry leading position in large, rapidly growing markets. Its diagnostics business includes BioReference Laboratories, the nation’s third largest clinical laboratory with a core genetic testing business. However, our proven model does not conclusively show that the stock is likely to beat earnings this quarter as along with a Zacks Rank #4 (Sell), it has an Earnings ESP of 0.00%.
Nevro Corp. (NYSE:NVRO) : Nevro, a global medical device company that works on the improvement of the quality of life of patients suffering from debilitating chronic pain. Like with the above two, our proven model does not conclusively show that the stock is likely to beat earnings this quarter. This because along with a Zacks Rank #4 the stock has an Earnings ESP of 0.00%.
Get The News You Want
Nevro Corp. Price and EPS Surprise
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.